Navigation Links
Amicus Therapeutics Presents Data From Preclinical and Phase 1,Studies of Amigal for Fabry Disease

Studies in Mice Show Reduction of Enzyme Substrate

CRANBURY, N.J., March 19, 2007 /PRNewswire/ -- Amicus Therapeutics, a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today that the Company will present results from studies of Amigal(TM) (migalastat hydrochloride, AT1001), Amicus' compound in development for the treatment of Fabry disease, at the of Medical Genetics (ACMG) Annual Meeting from March 21-25 in Nashville, TN. This presentation will include the first data from the Company demonstrating the reduction of globotriaosylceramide (GL-3), the lipid substrate that accumulates in Fabry disease, after oral administration of a pharmacological chaperone. These data were not available at the time of abstract submission but will be included in the presentation at the meeting.

Amigal is designed to selectively bind to and stabilize alpha- galactosidase A (alpha-GAL), the enzyme deficient in Fabry disease. This deficiency leads to lysosomal accumulation of GL-3, which is believed to cause the various symptoms of Fabry disease. Amigal facilitates proper trafficking of the enzyme to the lysosomes, the compartments in the cell where it is needed to break down GL-3.

At the ACMG meeting, Amicus scientists will present data from several studies that examined the in vitro and in vivo effects of Amigal in cell lines, mice and healthy volunteers. Among the key findings:

    - In vitro exposure to Amigal increased the level of alpha-GAL in cells

      derived from healthy volunteers and from Fabry patients.


    - Oral administration of Amigal resulted in a dose-dependent increase in

      alpha-GAL levels in various tissues of normal mice and Fabry mice

      genetically modified to produce alpha-GAL with a human missense

      mutation.


    - Oral administration of Amigal to healthy vo
'"/>




Page: 1 2 3

Related medicine technology :

1. Amicus Therapeutics Presents Positive Results From Phase 1 Clinical Studies of Plicera for Gaucher Disease
2. Amicus Therapeutics Presents Preclinical Data from Studies of Plicera for Gaucher Disease
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
5. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
6. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
7. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
8. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
(Date:5/29/2015)... Educating the community continues to be ... Advancement of Wound Care (AAWC), which was incorporated ... corporate partners, the Association provides medical professionals with ... website at http://aawconline.org/education-for-the-generalist/ . The portal is ... to various CME/CEU educational programs. This education is ...
(Date:5/28/2015)... 2015  Pharmaceutical companies and diagnostics companies ... and this is translating into a sizeable ... them. This according to Kalorama Information, a healthcare ... as mass spectrometry, electrophoresis and liquid chromatography ... drug targets and the validation of biomarkers, ...
(Date:5/28/2015)... 28, 2015  IRIDEX Corporation (NASDAQ: IRIX ) today ... James H. Mackaness is scheduled to present at the ... am PT in Los Angeles . ... accessed on the Event Calendar of the Investors section of ... webcast will be available shortly after the conclusion of the ...
Breaking Medicine Technology:The Association for the Advancement of Wound Care Educates the Public 2Report: Proteomics Research Market Reaches $1.6 Billion 2Report: Proteomics Research Market Reaches $1.6 Billion 3
... 2011   Denali Concrete Management Inc. (OTCBB: DCMG) ... the reverse acquisition of Denali by Can-Fite BioPharma Ltd. ... all the outstanding shares of EyeFite Ltd., a private ... Can-Fite an exclusive license over CF101 for ophthalmic indications. ...
... MESA, Ariz., Nov. 22, 2011 Matthew Likens, president ... global, commercial-stage medical device company pioneering aesthetic and medical ... scheduled to present at two upcoming healthcare  conferences:-- Tuesday, ... Jaffray Healthcare Conference in New York City, Nov. ...
Cached Medicine Technology:Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 2Denali Concrete Management Inc. Announces its Acquisition of CF101 for Ophthalmic Indications and the Completion of Above $6 Million Private Placement at $1.144 Per Share 3Ulthera CEO - Matthew Likens - to Present at Two Upcoming Healthcare Conferences 2
(Date:5/29/2015)... NJ (PRWEB) May 30, 2015 ... ever changing local and federal regulations, we provide ... of their patients who are suffering from pain, ... says Srinivas Nalamachu, MD, professor of rehabilitation medicine ... Institute in Overland Park, Kansas. , A new ...
(Date:5/29/2015)... M3 USA MDLinx.com, source of the ... specialties, now offers The Smartest Rheumatologist . The ... disorders ranging from Fibromyalgia and Osteoporosis, to Arthritis and ... MDLinx, and Caroline Tredway, editorial head of The Smartest ... have on the physicians who participate. Says Tredway, “With ...
(Date:5/29/2015)... The science of Follicular Unit Extraction ... more efficient methods of FUE hair transplantation have increased the ... the most cutting edge hair transplant methods being used to ... of extracting hair from the beard to the scalp. , ... correct male pattern baldness. Beard hair has a life ...
(Date:5/29/2015)... 29, 2015 Jan Wooden Howse lost her ... thing above all else: God does no wrong. , It’s ... her son’s passing is titled “God Does No Wrong.” It ... with great personal tragedy. , “My story has a ... to you into something productive, something healing,” Howse said. , ...
(Date:5/29/2015)... (PRWEB) May 29, 2015 World Patent ... products, announces that it has signed a 10 year ... patent that aims to let people learn about any ... real time. , "This is an exciting day for ... said Scott J. Cooper, CEO and Creative Director of ...
Breaking Medicine News(10 mins):Health News:PAINWeekEnd Kansas City: Pain Management CME for the Main Street Practitioner 2Health News:MDLinx Launches Smartest Rheumatologist 2Health News:Beard to Scalp Hair Transplant: Newest Advance in Hair Transplant Technology 2Health News:Turning grief from a child’s passing into virtue 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 2Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 3Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 4Health News:Licensing Alert! World Patent Marketing's Latest Blockbuster Licensing Deal Gets A New Twist on Technology With The Live Expert Chat Room 5
... technologies, testing methods, and processes to improve medical decontamination efforts. ... in other industries, and is using that knowledge to help improve ... ... Midbrook, Inc., a Jackson, MI based manufacturer of medical decontamination ...
... SAN ANTONIO, May 12 Eye Care Centers of ... acquired $65,360,000 of ECCA,s 10-3/4 percent Senior Subordinated Notes ... managed and/or advised by DDJ Capital Management, LLC were ... amount, plus accrued interest to the purchase date. The ...
... a meeting today with President Obama and business leaders, ... drew praise for their innovative employee health care and ... the meeting, President Obama referred to the participants, which ... President and CEO Steven Burd, as "some of the ...
... today,s release of the annual Social Security and ... two largest programs are on a troubled fiscal ... together on reforms of both programs aimed at ... to recognize the underlying structural factors contributing to ...
... Minn. -- Mayo Clinic and Grameen Healthcare are ... leveraging Mayo Clinic,s knowledge and expertise in health ... models. A multi-disciplinary team from Mayo Clinic has ... where it was agreed that following an initial ...
... FARMINGDALE, N.Y., May 12 Misonix, Inc. (Nasdaq: ... medical device technology, which in Europe is used for ... health conditions, has announced their attendance and participation in ... held in Los Angeles, CA, March 19-21, 2009. ...
Cached Medicine News:Health News:Midbrook Developing Decontamination Standards for Medical Industry 2Health News:Midbrook Developing Decontamination Standards for Medical Industry 3Health News:President Obama Praises Retailers as Part of the Health Care Solution 2Health News:Concord Coalition Says New Trustees' Report Demonstrates the Importance of Health Care Cost Control 2Health News:Mayo Clinic and Grameen Healthcare join forces to launch demonstration project 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 2Health News:Misonix Announces Participation in Annual Diabetic Foot Global Conference 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: